Publication Type:

Journal Article

Source:

Nanotechnology, Volume 22, Number 28 (2011)

URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-79959258332&partnerID=40&md5=9a3b907f8193ac492d7ed8a0eb8da2cb

Keywords:

Acute, acute granulocytic leukemia, Adverse effect, animal, Animals, Antibodies, Antigens, Aqueous phase, article, Au clusters, Average size, biocompatibility, Biomedical applications, Biosensing Techniques, Blood, Bovine, bovine serum albumin, Bovine serum albumins, Cancer cells, cattle, CD, CD33 antigen, Cell Line, Cell Survival, cell viability, Cells, Chemical detection, chemistry, Confocal imaging, cytokine, Cytokines, Differentiation, differentiation antigen, flow cytometry, Fluorescence, Fluorescent nanoclusters, Fourier Transform Infrared, genetic procedures, Gold, Gold compounds, Gold nanocluster, human, Human peripheral blood, Humans, immunology, immunophenotyping, inflammation, Inflammatory response, Infrared devices, infrared spectroscopy, Leukaemia cells, Leukemia, leukocyte antigen, lymphocyte, Lymphocytes, Medical applications, metabolism, methodology, Molecular receptors, Monoclonal, Monoclonal antibodies, monoclonal antibody, Myeloid, Myelomonocytic, Nanoclusters

Abstract:

Protein stabilized gold nanoclusters (Au-NCs) are biocompatible, near-infrared (NIR) emitting nanosystems having a wide range of biomedical applications. Here, we report the development of a Au-NC based targeted fluorescent nano-bioprobe for the flow-cytometric detection of acute myeloid leukaemia (AML) cells. Au-NCs with ∼ 25-28 atoms showing bright red-NIR fluorescence (600-750nm) and average size of ∼ 0.8nm were prepared by bovine serum albumin assisted reduction-cum-stabilization in aqueous phase. The protein protected clusters were conjugated with monoclonal antibody against CD33 myeloid antigen, which is overexpressed in ∼ 99.2% of the primitive population of AML cells, as confirmed by immunophenotyping using flow cytometry. Au-NC-CD33 conjugates having average size of ∼ 12nm retained bright fluorescence over an extended duration of ∼ a year, as the albumin protein protects Au-NCs against degradation. Nanotoxicity studies revealed excellent biocompatibility of Au-NC conjugates, as they showed no adverse effect on the cell viability and inflammatory response. Target specificity of the conjugates for detecting CD33 expressing AML cells (KG1a) in flow cytometry showed specific staining of ∼ 95.4% of leukaemia cells within 1-2h compared to a non-specific uptake of ∼ 8.2% in human peripheral blood cells (PBMCs) which are CD33low. The confocal imaging also demonstrated the targeted uptake of CD33 conjugated Au-NCs by leukaemia cells, thus confirming the flow cytometry results. This study demonstrates that novel nano-bioprobes can be developed using protein protected fluorescent nanoclusters of Au for the molecular receptor targeted flow cytometry based detection and imaging of cancer cells. © 2011 IOP Publishing Ltd.

Notes:

cited By 15

Cite this Research Publication

A. Retnakumari, Jayasimhan, J., Chandran, P., Menon, D., Nair, S., Ullas Mony, and Koyakutty, M., “CD33 monoclonal antibody conjugated Au cluster nano-bioprobe for targeted flow-cytometric detection of acute myeloid leukaemia”, Nanotechnology, vol. 22, 2011.